Anti-PLA2R1 Antibodies Containing Sera Induce In Vitro Cytotoxicity Mediated by Complement Activation
Table 2
Factors associated with ( patients treated with rituximab).
()
()
value
Age
0.46
Sex ratio (M/F)
10/2
19/6
>0.99
Proteinuria at diagnosis (g/g)
6.65 (5.75; 9.86)
4.90 (3.26; 7.68)
0.03
Anti-PLA2R1 total IgG (RU/ml) at diagnosis
192 (120; 686)
94 (33; 199)
0.01
Anti-PLA2R1 IgG4 (RU/ml) at diagnosis
1840 (322; 3990)
1338 (220–3461)
0.62
Spreaders at diagnosis
10/12 (83%)
12/25 (48%)
0.07
Proteinuria at month 6 (g/g)
3.70 (2.51; 5.60)
1.21 (0.30; 2.32)
0.001
Remission at month 6
5/12 (42%)
20/25 (80%)
0.03
Time to remission (months)
0.02
Data are presented as (%) or or as median with interquartile range. Remission is defined as g/g and serum g/l. Spreaders are defined by samples with anti-CysR reactivity with additional anti-CTLD1 and/or anti-CTLD7 activities additional to anti-CysR reactivity.
